IN8bio Issues Stock Inducement Grant Under Nasdaq Rule 5635(c)(4)
IN8bio has disclosed a stock inducement grant to a new employee under a Nasdaq listing rule exemption for equity compensation.
Biopharmaceutical company IN8bio has reported the issuance of an inducement grant to a newly hired employee, disclosing the action in accordance with Nasdaq Listing Rule 5635(c)(4), which permits companies to award equity compensation to new hires without prior shareholder approval under specified conditions.
The rule, a standard mechanism in the biotechnology and pharmaceutical sectors, allows publicly traded companies listed on Nasdaq to grant stock options or other equity awards as an inducement for individuals to join the firm. Such grants must be disclosed publicly and are subject to strict eligibility and structural requirements under Nasdaq's governance framework.
Read more Snorkel AI Secures $350 Million in Fresh Funding Round →
IN8bio, a clinical-stage company focused on gamma-delta T cell therapies for cancer treatment, has utilized this mechanism to attract talent, a common practice among early- and mid-stage biotech firms competing for specialized scientific and executive personnel in a tight labor market.
The disclosure did not detail the specific terms of the grant, including the number of shares, the exercise price, or the identity of the recipient, beyond what was required under the applicable Nasdaq reporting framework. Investors and analysts typically monitor such grants as indicators of hiring activity and potential operational expansion at clinical-stage biotechs.
Continue reading at GlobeNewswire - Industry News on Financial Services.
